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Introduction {#jah31574-sec-0005}
============

Carotid intima--media thickness (cIMT) measured by ultrasound is a noninvasive, safe, inexpensive, reproducible, and well‐validated surrogate marker of early atherosclerosis, vascular aging, and adaptive response to an increased hemodynamic load.[1](#jah31574-bib-0001){ref-type="ref"}, [2](#jah31574-bib-0002){ref-type="ref"}, [3](#jah31574-bib-0003){ref-type="ref"}, [4](#jah31574-bib-0004){ref-type="ref"} Increased cIMT is independently associated with future cardiovascular events.[5](#jah31574-bib-0005){ref-type="ref"}, [6](#jah31574-bib-0006){ref-type="ref"}, [7](#jah31574-bib-0007){ref-type="ref"} This relationship has promoted the use of cIMT in pathophysiological studies and clinical trials, as either a secondary end point or a surrogate marker of risk for cardiovascular events.[8](#jah31574-bib-0008){ref-type="ref"}

It has also been noted that cIMT increases in participants with a history of hypertension (a major risk factor for cardiovascular events),[9](#jah31574-bib-0009){ref-type="ref"}, [10](#jah31574-bib-0010){ref-type="ref"}, [11](#jah31574-bib-0011){ref-type="ref"}, [12](#jah31574-bib-0012){ref-type="ref"} reflecting the vascular damage caused by this condition. Evidence is scarce, however, regarding the association between blood pressure (BP) and cIMT in both hypertensive and nonhypertensive persons. An association of higher BP with higher cIMT, even in nonhypertensive patients, would support identification of early vascular damage using cIMT prior to overt hypertension---an aspect of noteworthy clinical implications. To identify whether a BP cutoff for increased cIMT exists or if BP is linearly associated with increased cIMT, the functional form of the association between BP and cIMT needs to be evaluated.

We intended to determine whether BP was linearly (or nonlinearly) associated with cIMT in participants with and without hypertension.

Methods {#jah31574-sec-0006}
=======

Study Population {#jah31574-sec-0007}
----------------

The STANISLAS cohort is a single‐center familial longitudinal cohort composed of 1006 families (4295 participants) from the Nancy region of France who were recruited during 1993--1995 at the Center for Preventive Medicine. This cohort was established with the primary objective of investigating gene--gene and gene--environment interactions in the field of cardiovascular diseases. The families were deemed healthy and free of declared acute and/or chronic illness so as to assess the effect of genetics on the variability of intermediate phenotypes on the transition toward pathology.

From 2011 to 2015 onward, 1218 survivors of the original cohort underwent their fourth examination at our department, as described previously.[13](#jah31574-bib-0013){ref-type="ref"} For the present study, 696 adult participants (ie, persons with ≥18 years and cIMT measurements) were included (Figure [1](#jah31574-fig-0001){ref-type="fig"}).

![Study flowchart. ABPM indicates ambulatory blood pressure measurement; HTN, hypertension.](JAH3-5-e003529-g001){#jah31574-fig-0001}

The research protocol was approved by the local ethics committee in Nancy, France, and all study participants gave written informed consent to participate. The informed written consent was approved previously by the local ethics committee ([ClinicalTrials.gov](http://ClinicalTrials.gov) identifier NCT01391442).

Study Design {#jah31574-sec-0008}
------------

In this cross‐sectional study, all participants were scheduled to attend the Centre d\'Investigation Clinique Plurithématique Pierre Drouin at Nancy Hospital Center at 8 [am]{.smallcaps} after a 12‐ to 14‐hour fast. Blood samples were taken to measure glucose and cholesterol.

Medical history, medications, anthropometric parameters (body mass index \[BMI\] was calculated from height and weight \[in kg/m^2^\]), BP, pulse‐wave velocity, and cIMT were also recorded.

Carotid Intima--Media Thickness {#jah31574-sec-0009}
-------------------------------

To measure the cIMT, a B‐mode ultrasound examination of the right common carotid artery was performed by experienced sonographers. The investigations were performed in a controlled environment after 10 minutes rest in supine position. IMT was measured by an echo tracking system (Wall Track System; Pie Medical) on the right common carotid artery at 1 to 2 cm below the carotid bifurcation. The Wall Track System measures the parameters in 2 dimensions on 1 radiofrequency line perpendicular to the artery (7.5 MHz probe). The cIMT was assessed at the far wall. The retained value was the mean of 4 measurements.[3](#jah31574-bib-0003){ref-type="ref"}, [8](#jah31574-bib-0008){ref-type="ref"}, [14](#jah31574-bib-0014){ref-type="ref"}, [15](#jah31574-bib-0015){ref-type="ref"} The interobserver agreement of IMT assessment was analyzed by intraclass correlation coefficients and was classified as excellent (intraclass correlation coefficient \>0.75) for all operators (intraclass correlation coefficients 0.870--0.919). The mean absolute and relative difference compared with a senior operator was \<5% for all operators.

Blood Pressure {#jah31574-sec-0010}
--------------

Office BP was measured 3 times in all participants, at 1‐minute intervals, using an electronic sphygmomanometer after the participant had rested for at least 10 minutes. Office BP was calculated as the mean of the 3 measurements.

All participants underwent a 24‐hour recording of ambulatory BP (ABP) using the Spacelabs 90207 ambulatory monitor (Spacelabs Medical). The monitoring cuff was placed around the participant\'s nondominant arm. The BP system was programmed to measure every 15 minutes from 6 [am]{.smallcaps} to 10 [pm]{.smallcaps} and every 30 minutes from 10 [pm]{.smallcaps} to 6 [am]{.smallcaps}. Self‐reported sleep--wake times have been used to divide ABP monitoring data into daytime and nocturnal periods. The BP indices were calculated from 24‐hour, daytime, and nighttime measurements. Furthermore, participants had to complete a diary describing their main daily activities (eg, eat, sleep) and were asked to avoid excessive exercise during the 24‐hour recording. Central reading of the recordings was performed by a trained technician blinded from participant clinical features. Data were considered for further analysis if they met the following criteria: The recording lasted ≥24 hours, ≥70% of the expected number of readings were available, the data were not missing for \>2 consecutive hourly intervals, and ≥2 valid measurements were obtained per hour.[16](#jah31574-bib-0016){ref-type="ref"}

Definition of hypertension history was based on assistant physician registries and/or ongoing treatment for hypertension. Participants without these criteria were considered to have no history of hypertension.

Statistical Methods {#jah31574-sec-0011}
-------------------

Proportions were compared using chi‐square tests and were expressed as number (proportion as percentage). Continuous variables were expressed as mean±SD or median (interquartile range \[IQR\]) and compared using a *t* test or Mann--Whitney tests, according to the normality of the variables.

We focused on the outcome of cIMT, either continuous or dichotomized with a cutoff of 900 μm, a value that has been defined as definitely abnormal.[17](#jah31574-bib-0017){ref-type="ref"}

Logistic (for dichotomous cIMT) and linear (for continuous cIMT) regressions were performed to assess the associations between the dependent variable (cIMT) and independent variables (BP, age, sex, total cholesterol, smoking status, glycemia, and BMI). To assess the detailed influence of BP in cIMT measurements, we performed 3 different models: 1 unadjusted for BP, 1 adjusted for 24‐hour systolic BP (SBP), and 1 adjusted for 24‐hour diastolic BP (DBP). Each model was further and progressively adjusted for age, sex, smoking status, total cholesterol, glycemia, and BMI.

We also wanted to determine whether a nonlinear link could be detected between BP and IMT (Table S1). Restricted cubic splines of BP variables were computed with a macro in SAS (SAS Institute) that consisted of transforming the independent variable 1 linear variable and k−2 cubic variables, in which k is the number of knots (at least 3, more often between 3 and 5 is sufficient). Three knots were used and fixed to the 10th, 50th, and 90th percentiles, according to Harrel\'s recommendation.[18](#jah31574-bib-0018){ref-type="ref"} Testing the log‐linear association between the exposure and the outcome consists of testing the nullity of the coefficient attributed to the cubic part (*P*\<0.05 means that the coefficient is significantly different from zero, indicating non--log‐linearity).

The interaction between BP and hypertension on cIMT was also assessed in crude logistic regression and linear regression models, that is, in models including only the terms BP and hypertension and an interaction term of BP times hypertension (Table S2).

*P*\<0.05 was considered statistically significant. All analyses were performed using SAS version 9.3.

Results {#jah31574-sec-0012}
=======

Participants\' Baseline Characteristics {#jah31574-sec-0013}
---------------------------------------

Participants with history of hypertension were significantly older (60.8±5.1 versus 58.4±5.9 years, *P*\<0.001), had higher BMI (28.1 \[IQR 25.3--32.0\] versus 25.1 \[IQR 22.8--27.9\], *P*\<0.001), had lower cholesterol levels (low‐density lipoprotein 1.35±0.37 versus 1.48±0.31 mmol/L, *P*\<0.001; high‐density lipoprotein 0.55±0.14 versus 0.62±0.15 mmol/L, *P*\<0.001), were more often diabetic (12% versus 3%, *P*\<0.001), had higher SBP and DBP (SBP 135±15 versus 126±15 mm Hg, *P*\<0.001; DBP 76±9 versus 74±9 mm Hg, *P*=0.001), higher cIMT (713 μm \[IQR 633--817 μm\] versus 684 μm \[IQR 607--776 μm\], *P*=0.001), and more participants with cIMT \>900 μm (15% versus 6%, *P*\<0.001) (Table [1](#jah31574-tbl-0001){ref-type="table-wrap"}).

###### 

Comparison of the Characteristics of Patients With Previously Known HTN History and Previously Unknown HTN Status

                                   HTN History (n=217)   No HTN History (n=479)   *P* Value
  -------------------------------- --------------------- ------------------------ -----------
  Age, y                           60.8±5.1              58.4±5.9                 \<0.001
  Male                             54%                   48%                      0.149
  Height, m                        1.66 (1.58--1.73)     1.67 (1.60--1.74)        0.104
  Weight, kg                       78.8 (67.7--89.7)     70.1 (61.6--80.8)        \<0.001
  BMI, kg/m²                       28.1 (25.3--32.0)     25.1 (22.8--27.9)        \<0.001
  Smoking                          13%                   12%                      0.602
  eGFR, mL/min/1.73 m²             87.6 (77.2--96.0)     91.0 (81.6--97.8)        0.005
  eGFR \<60 mL/min/1.73 m²         2%                    2%                       0.772
  Total cholesterol, g/L           2.16±0.43             2.31±0.35                \<0.001
  LDL, g/L                         1.35±0.37             1.48±0.31                \<0.001
  HDL, g/L                         0.55±0.14             0.62±0.15                \<0.001
  Hypercholesterolemia treatment   42%                   13%                      \<0.001
  Glycemia, g/L                    0.95 (0.88--1.03)     0.90 (0.84--0.96)        \<0.001
  Diabetes                         12%                   3%                       \<0.001
  Diabetes treatment               12%                   2%                       \<0.001
  Antihypertensive treatment       100%                  0                        \<0.001
  SBP, mm Hg, office measure       135±15                126±15                   \<0.001
  DBP, mm Hg, office measure       76±9                  74±9                     0.001
  Nocturnal SBP, mm Hg             116±12                111±10                   \<0.001
  Diurnal SBP, mm Hg               129±12                125±10                   \<0.001
  24‐h SBP, mm Hg                  124±11                120±9                    \<0.001
  cIMT, μm                         713 (633--817)        684 (607--776)           0.001
  cIMT \>900 μm                    15%                   6%                       \<0.001

Parametric tests were used for normally distributed variables; nonparametric tests were used for positively skewed variables (weight, BMI, glycemia, and IMT). BMI indicates body mass index; cIMT, carotid intima--media thickness; DBP, diastolic blood pressure; eGFR, estimated glomerular filtration rate; HDL, high‐density lipoproteins; HTN, hypertension; LDL, low‐density lipoproteins; SBP, systolic blood pressure.

Associations Between IMT and Hypertension Status {#jah31574-sec-0014}
------------------------------------------------

In the univariable model, participants with history of hypertension were more likely to have cIMT \>900 μm (odds ratio 2.675 \[95% CI 1.571--4.554\], *P*\<0.001) and had higher mean cIMT (β=45.30 \[95% CI 20.80--69.70\], *P*\<0.001) compared with those without history of hypertension. These associations remained significant after adjustment for BP variables (24‐hour SBP and DBP) (Table [2](#jah31574-tbl-0002){ref-type="table-wrap"}). We adjusted for sex, age, and smoking status (model 1) plus total cholesterol and glycemia (model 2), retaining the described associations in the "crude model" (Table [2](#jah31574-tbl-0002){ref-type="table-wrap"}); however, when adjusting model 2 plus BMI (model 3), the association between having history of hypertension and increased cIMT (both categorical and continuous) was no longer significant (cIMT \>900 μm: odds ratio 1.603 \[95% CI 0.868--2.959\], *P*=0.132; cIMT continuous: β=12.70 \[95% CI −13.70 to 39.10\], *P*=0.345) (Table [2](#jah31574-tbl-0002){ref-type="table-wrap"}).

###### 

Crude and Adjusted Association Between HTN History and IMT Expressed Either as a Dichotomous or Continuous Variable

  Variables (n=696)                                                                   IMT Cutoff 900 μm      Continuous IMT                                
  ----------------------------------------------------------------------------------- ---------------------- ---------------- ---------------------------- ---------
  Model without adjustment on cardiovascular risk factors                                                                                                  
  Without adjustment for BP                                                           2.675 (1.571--4.554)   \<0.001          45.265 (20.781--69.748)      \<0.001
  With adjustment for 24‐h SBP                                                        2.253 (1.300--3.906)   0.004            34.361 (9.570--59.151)       0.007
  With adjustment for 24‐h DBP                                                        2.675 (1.571--4.555)   \<0.001          45.194 (20.719--69.670)      \<0.001
  Model adjusted for age, sex, and smoking status                                                                                                          
  Without adjustment for BP                                                           2.229 (1.284--3.868)   0.004            32.060 (7.205--56.915)       0.012
  With adjustment for 24‐h SBP                                                        2.020 (1.149--3.551)   0.014            25.789 (0.654--50.923)       0.044
  With adjustment for 24‐h DBP                                                        2.229 (1.284--3.869)   0.004            32.033 (7.200--56.867)       0.012
  Model adjusted for age, sex, smoking status, total cholesterol, and glycemia                                                                             
  Without adjustment for BP                                                           2.107 (1.179--3.765)   0.012            29.562 (3.656--55.478)       0.025
  With adjustment for 24‐h SBP                                                        1.969 (1.094--3.546)   0.024            24.808 (−1.254 to 50.870)    0.062
  With adjustment for 24‐h DBP                                                        2.104 (1.176--3.764)   0.012            29.675 (3.775--55.576)       0.025
  Model adjusted for age, sex, smoking status, total cholesterol, glycemia, and BMI                                                                        
  Without adjustment for BP                                                           1.603 (0.868--2.959)   0.132            12.689 (−13.680 to 39.058)   0.345
  With adjustment for 24‐h SBP                                                        1.523 (0.822--2.820)   0.181            9.193 (−17.238 to 35.624)    0.495
  With adjustment for 24‐h DBP                                                        1.598 (0.864--2.956)   0.135            12.691 (−13.650 to 39.032)   0.345

Analyses performed with logistic (for dichotomous IMT) and linear (for continuous IMT) regressions. BMI indicates body mass index; BP, blood pressure; DBP, diastolic blood pressure; HTN, hypertension; IMT, intima--media thickness; OR, odds ratio; SBP, systolic blood pressure.

Associations Between IMT and BP {#jah31574-sec-0015}
-------------------------------

Using spline‐based analyses, we did not find evidence of a nonlinear association of BPs (SBP, DBP, or mean for 24 hours, daytime, nighttime, or office) with cIMT (Table S1). In addition, we found no significant evidence of a differential association of BP with cIMT in participants with and without hypertension (Table S2).

We plotted the risk of having cIMT \>900 μm according to history of hypertension in Figure [2](#jah31574-fig-0002){ref-type="fig"}. In participants with history of hypertension, the risk of cIMT \>900 μm gradually rose from \<5% in participants with 24‐hour SBP \<110 mm Hg to \>20% in participants with 24‐hour SBP \>140 mm Hg (Figure [2](#jah31574-fig-0002){ref-type="fig"}). Likewise, in participants without history of hypertension, the risk of cIMT \>900 μm gradually rose from \<5% in participants with 24‐hour SBP \<110 mm Hg to almost 10% in participants with 24‐hour SBP \>130 mm Hg. Similar trends were observed for daytime and nighttime SBP (except for nighttime BP in participants without a history of hypertension, a biphasic pattern was observed, peaking at 115 mm Hg) (Figure [2](#jah31574-fig-0002){ref-type="fig"}).

![Risk of having a carotid IMT \>900 μm according to previous HTN history. HTN, hypertension; IMT, intima--media thickness; SBP, systolic blood pressure.](JAH3-5-e003529-g002){#jah31574-fig-0002}

Given this absence of significant interaction, we studied the entire cohort in further statistical models. Participants with higher SBP (24 hours, diurnal, nocturnal, and office) were significantly more likely to have cIMT \>900 μm. SBP was also significantly associated with cIMT (expressed as a linear continuous variable) in univariable linear regression. In contrast, DBP was not associated with cIMT values (Table [3](#jah31574-tbl-0003){ref-type="table-wrap"}). After multivariable adjustment including age, sex, smoking status, total cholesterol, glycemia, BMI (model 3 in Table [3](#jah31574-tbl-0003){ref-type="table-wrap"}), and antihypertensive treatment (calcium channel blockers, angiotensin‐converting enzyme inhibitors, angiotensin receptors blockers, and beta blockers) (Tables S3 and S4), these associations became weaker, although they were significant for continuous cIMT. In model 3, for example, each 5‐mm Hg increase in 24‐hour SBP was associated with a ≈7‐μm increase in cIMT (IMT continuous: β=7.292 \[95% CI 1.266--13.317\], *P*=0.018), and each 5‐mm Hg increase in daytime SBP was associated with a ≈8‐μm increase in cIMT (IMT continuous: β=7.696 \[95% CI 2.017--13.374\], *P*=0.008) (Table [3](#jah31574-tbl-0003){ref-type="table-wrap"}).

###### 

Association of the IMT With BP Variables

  Variables (n=696)                                                                        IMT Cutoff 900 μm      Continuous IMT                              
  ---------------------------------------------------------------------------------------- ---------------------- ---------------- -------------------------- ---------
  Model adjusted for HTN                                                                                                                                      
  Office SBP                                                                               1.150 (1.062--1.246)   \<0.001          8.358 (4.698--12.019)      \<0.001
  24‐h SBP                                                                                 1.192 (1.053--1.349)   0.006            11.542 (5.896--17.187)     \<0.001
  Diurnal SBP                                                                              1.191 (1.059--1.339)   0.004            11.367 (6.065--16.670)     \<0.001
  Nocturnal SBP                                                                            1.152 (1.023--1.297)   0.019            8.925 (3.509--14.342)      0.001
  Office DBP                                                                               1.168 (1.004--1.359)   0.045            9.546 (2.936--16.156)      0.005
  24‐h DBP                                                                                 0.976 (0.820--1.161)   0.781            4.699 (−3.005 to 12.403)   0.232
  Diurnal DBP                                                                              0.989 (0.840--1.164)   0.891            4.838 (−2.390 to 12.067)   0.189
  Nocturnal DBP                                                                            0.961 (0.809--1.142)   0.651            3.185 (−4.348 to 10.718)   0.407
  Model adjusted for HTN, age, sex, smoking status                                                                                                            
  Office SBP                                                                               1.115 (1.023--1.216)   0.014            6.055 (2.150--9.960)       0.002
  24‐h SBP                                                                                 1.134 (0.994--1.294)   0.062            8.350 (2.365--14.335)      0.006
  Diurnal SBP                                                                              1.140 (1.005--1.292)   0.041            8.648 (3.010--14.287)      0.003
  Nocturnal SBP                                                                            1.103 (0.975--1.248)   0.118            6.023 (0.416--11.630)      0.035
  Office DBP                                                                               1.105 (0.941--1.298)   0.224            8.585 (1.678--15.492)      0.015
  24‐h DBP                                                                                 0.948 (0.783--1.147)   0.580            6.085 (−2.149 to 14.319)   0.147
  Diurnal DBP                                                                              0.970 (0.810--1.161)   0.738            6.617 (−1.109 to 14.342)   0.093
  Nocturnal DBP                                                                            0.932 (0.775--1.121)   0.455            3.586 (−4.303 to 11.475)   0.372
  Model adjusted for HTN, age, sex, smoking status, total cholesterol, and glycemia                                                                           
  Office SBP                                                                               1.105 (1.011--1.208)   0.027            5.930 (1.956--9.903)       0.004
  24‐h SBP                                                                                 1.118 (0.976--1.281)   0.106            7.931 (1.827--14.035)      0.011
  Diurnal SBP                                                                              1.123 (0.987--1.278)   0.078            8.249 (2.490--14.008)      0.005
  Nocturnal SBP                                                                            1.095 (0.966--1.241)   0.157            5.714 (0.043--11.385)      0.048
  Office DBP                                                                               1.069 (0.906--1.262)   0.430            8.291 (1.277--15.304)      0.021
  24‐h DBP                                                                                 0.926 (0.763--1.124)   0.437            5.656 (−2.614 to 13.925)   0.180
  Diurnal DBP                                                                              0.943 (0.785--1.133)   0.530            6.109 (−1.666 to 13.885)   0.123
  Nocturnal DBP                                                                            0.928 (0.771--1.117)   0.428            3.490 (−4.411 to 11.392)   0.386
  Model adjusted for HTN, age, sex, smoking status, total cholesterol, glycemia, and BMI                                                                      
  Office SBP                                                                               1.094 (0.999--1.197)   0.051            5.175 (1.243--9.107)       0.010
  24‐h SBP                                                                                 1.119 (0.976--1.283)   0.107            7.292 (1.266--13.317)      0.018
  Diurnal SBP                                                                              1.125 (0.987--1.281)   0.077            7.696 (2.017--13.374)      0.008
  Nocturnal SBP                                                                            1.094 (0.964--1.242)   0.162            5.127 (−0.483 to 10.736)   0.073
  Office DBP                                                                               1.046 (0.884--1.238)   0.601            6.713 (−0.257 to 13.682)   0.059
  24‐h DBP                                                                                 0.946 (0.776--1.154)   0.586            6.312 (−1.786 to 14.409)   0.126
  Diurnal DBP                                                                              0.959 (0.795--1.157)   0.664            6.532 (−1.086 to 14.149)   0.093
  Nocturnal DBP                                                                            0.947 (0.784--1.145)   0.576            4.186 (−3.557 to 11.928)   0.289

Analyses performed with logistic (for dichotomous IMT) and linear (for continuous IMT) regressions. BMI indicates body mass index; BP, blood pressure; DBP, diastolic blood pressure; HTN, hypertension; IMT, intima‐media thickness; OR, odds ratio; SBP, systolic blood pressure.

Discussion {#jah31574-sec-0016}
==========

We found that SBP is linearly and continuously associated with cIMT regardless of hypertension status. In our study, SBP had a linear association with cIMT throughout the SBP spectrum (even after adjustment for potential confounders, including antihypertensive treatment). We carefully searched for evidence of nonlinear associations using the most appropriate statistical methods (ie, spline‐based analysis). To the best of our knowledge, we are the first to perform this precise functional form of analysis for the association of BP with cIMT. The absence of a natural cutoff for the association between BP and cIMT suggests a gradual and continuous increase in the risk of vascular damage with higher levels of BP (even in normotensive participants), as observed for hard end points in the field of hypertension.

Moreover, our study is one of the largest population‐based studies to assess the association between BP, assessed by 24‐hour ABP monitoring, and cIMT.[19](#jah31574-bib-0019){ref-type="ref"}

cIMT: A Marker of Vascular Damage {#jah31574-sec-0017}
---------------------------------

The accumulated evidence suggests that increased cIMT is associated with cardiovascular risk factors and adverse events.[6](#jah31574-bib-0006){ref-type="ref"}, [20](#jah31574-bib-0020){ref-type="ref"}, [21](#jah31574-bib-0021){ref-type="ref"}, [22](#jah31574-bib-0022){ref-type="ref"}, [23](#jah31574-bib-0023){ref-type="ref"} Moreover, cIMT changes over time can be assessed to monitor prognosis and/or response to treatment (eg, antihypertensive therapy).[24](#jah31574-bib-0024){ref-type="ref"}, [25](#jah31574-bib-0025){ref-type="ref"} Some studies suggest that cIMT can provide prognostic information above and beyond traditional risk factors.[17](#jah31574-bib-0017){ref-type="ref"}, [21](#jah31574-bib-0021){ref-type="ref"}, [26](#jah31574-bib-0026){ref-type="ref"} More recently, the prognostic utility of cIMT beyond that of other well‐known and validated risk factors has been questioned.[27](#jah31574-bib-0027){ref-type="ref"} Nevertheless, this does not impair the value of cIMT as an early marker of atherosclerosis, arterial hypertrophy or hyperplasia induced by pressure overload, and age‐related sclerosis. Consequently, cIMT represents an integrative measure of vascular damage rather than a marker of a particular isolated condition.[12](#jah31574-bib-0012){ref-type="ref"}, [28](#jah31574-bib-0028){ref-type="ref"}

Because cIMT is a very sensitive tool that can identify mild vascular damage, we could identify as much as 6% of participants without hypertension (based on clinical records plus ABP measurement) with increased cIMT (\>900 μm). In a way, this low threshold of detection enables us to study the link between BP values that are considered to be within the normal range and vascular damage.

Association of Hypertension and BP With cIMT {#jah31574-sec-0018}
--------------------------------------------

Increased SBP (regardless of the used method) is an important determinant of cIMT, presumably an augmentation of the intima--media complex.[29](#jah31574-bib-0029){ref-type="ref"}, [30](#jah31574-bib-0030){ref-type="ref"} As our study confirmed, participants with history of hypertension and those who had hypertension detected on 24‐hour ABP monitoring (but without a previous hypertension diagnosis) are likely to have higher cIMT values (Table S5). Why only SBP (and not DBP) was associated with increased cIMT deserves some comment. A previous study described SBP (and not DBP) as an independent predictor of increased cIMT.[12](#jah31574-bib-0012){ref-type="ref"} Likewise, another study found that SBP (24 hours, daytime, and nighttime) was significantly correlated with cIMT, even after adjustment for age, sex, and smoking. In that study, DBP was again not associated with cIMT measurement.[31](#jah31574-bib-0031){ref-type="ref"} These findings have also been reported in other studies[32](#jah31574-bib-0032){ref-type="ref"}, [33](#jah31574-bib-0033){ref-type="ref"}, [34](#jah31574-bib-0034){ref-type="ref"}, [35](#jah31574-bib-0035){ref-type="ref"} and suggest that SBP may induce higher pressure overload and thus induce more arterial hypertrophy or hyperplasia than DBP. Moreover, some authors argued that SBP may be a more important risk factor for atherosclerosis and cardiovascular disease than DBP.[34](#jah31574-bib-0034){ref-type="ref"}, [35](#jah31574-bib-0035){ref-type="ref"}

We provided strong evidence for a continuum of vascular damage caused by higher BP, even in participants without a history of hypertension . In addition, the risk of cIMT \>900 μm increased 2‐fold from \<110 mm Hg to \>130 mm Hg for 24‐hour SBP in both hypertensive and nonhypertensive participants (Figure [2](#jah31574-fig-0002){ref-type="fig"}). In a way, our results highlight the detrimental effect of BP in a range currently considered to be normal. This paradigm of a gradual continual increase of risk with higher values of a variable is well known in other fields of medicine, for instance, gradually increasing risk of clinical events is observed with higher fasting glucose values, even outside of the range of diabetes definition.[36](#jah31574-bib-0036){ref-type="ref"} This has also been described in the field of hypertension, with the risk of hard clinical end points gradually increasing with higher BP values above a certain cutoff.[37](#jah31574-bib-0037){ref-type="ref"}

This finding can explain, to some extent, the association of "prehypertension" with poorer outcome.[38](#jah31574-bib-0038){ref-type="ref"}, [39](#jah31574-bib-0039){ref-type="ref"} Because the process is gradual, prehypertension is moderately associated with higher risk for events, possibly because of greater vascular damage, as highlighted by our results. In addition, our results are of interest in the interpretation of the recently published SPRINT trial. In the SPRINT trial,[4](#jah31574-bib-0004){ref-type="ref"} an office SBP \<120 mm Hg (intensive treatment) significantly reduced the primary composite outcome (of myocardial infarction, other acute coronary syndromes, stroke, heart failure, or death from cardiovascular causes) and all‐cause mortality (intensive treatment: hazard ratio 0.75 \[95% CI 0.64--0.89\], *P*\<0.001, and 0.73 \[95% CI 0.60--0.90\], *P*=0.003, respectively) compared with a standard strategy (target SBP \<140 mm Hg). The better clinical outcome associated with intensive treatment might be partially linked to a lesser degree of vascular damage in patients with more strict BP control. Our results greatly support this hypothesis, with the number of participants with cIMT \>900 µm being decreased 2‐fold in hypertensive participants with 24‐hour SBP \<110 mm Hg compared with participants at the usual 24‐hour SBP target of 130 mm Hg (Figure [2](#jah31574-fig-0002){ref-type="fig"}). Increasing subclinical vascular damage in participants with BP at the high end of the normal range (ie, office SBP between 120 and 139 mm Hg, ambulatory SBP between 110 and 130 mm Hg) might be an important physiopathological process contributing to the disruptive results of the SPRINT trial. These results were also confirmed in a recent meta‐analysis[39](#jah31574-bib-0039){ref-type="ref"} in which intensive lowering of BP provided greater vascular protection than standard regimens, especially in high‐risk patients (eg, those with vascular disease, renal disease, or diabetes), including those with SBP \<140 mm Hg.

Limitations {#jah31574-sec-0019}
-----------

The main limitation of our study is its observational design, based on a cross‐sectional evaluation; therefore, only associations between study variables could be detected, and causality could not be inferred. These associations are likely to be reproducible by other observers (we demonstrated excellent interobserver agreement). In addition, given our sample size, we could not adjust our analysis for every possible cardiovascular risk variable. Last, the conclusions of this analysis cannot be generalized to general hypertensive population, as they refer to a sample of hypertension subjects with good BP control on average.

Conclusions {#jah31574-sec-0020}
===========

SBP was linearly and continuously associated with higher cIMT in both hypertensive and nonhypertensive participants, suggesting a detrimental effect of BP on the vascular tree prior to overt hypertension. Similarly, it suggests a detrimental effect of BP at the higher end of the normal range in treated hypertensive patients.
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